8 reports

Significant survival advantages for the abatacept group were demonstrated at one-year post-transplant.

  • Immunotherapy
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Bristol-Myers Squibb Company

Significant survival advantages for the abatacept group were demonstrated at one-year post-transplant.

  • Immunotherapy
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Bristol-Myers Squibb Company

Novartis Pharmaceuticals registered a one year, multicenter, open-label, single arm, pilot Phase III study of the renal safety of Everolimus in addition to Cyclosporine microemulsion in cardiac transplant recipients.

  • Endometrial Cancer
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Bristol-Myers Squibb Company

One patient developed symptomatic congestive heart failure.

  • Endometrial Cancer
  • Targeted Therapy
  • Vaccine
  • United States
  • Bristol-Myers Squibb Company

One patient developed symptomatic congestive heart failure.

  • Endometrial Cancer
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Bristol-Myers Squibb Company

One patient developed symptomatic congestive heart failure.

  • Endometrial Cancer
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Bristol-Myers Squibb Company

One patient developed symptomatic congestive heart failure.

  • Endometrial Cancer
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Bristol-Myers Squibb Company

IN ADDITION, TWO GRADE ## CARDIAC EVENTS OCCURRED, RESULTING IN ONE HEART FAILURE AND ONE TACHYCARDIA.

  • Targeted Therapy
  • Therapy
  • Vaccine
  • World
  • Bristol-Myers Squibb Company